The functionality of probiotics is highly influenced by culture and processing conditions, making batch stability validation through human or mouse trials impractical. Here, we employed a comprehensive approach using <i>Caenorhabditis elegans</i>, mouse and human models to elucidate the beneficial effects of <i>Lactiplantibacillus plantarum</i> TWK10 (TWK10). In <i>C. elegans</i>, TWK10 administration significantly prolonged lifespan by 26.1&#
xa0;&#
xb1;&#
xa0;11.9 % (<i>p</i>&#
xa0;<&#
xa0;0.05), enhanced locomotion (<i>p</i>&#
xa0;<&#
xa0;0.01) and muscle mass (<i>p</i>&#
xa0;<&#
xa0;0.001), elevated glycogen storage (<i>p</i>&#
xa0;<&#
xa0;0.05), and reduced lipid accumulation (<i>p</i>&#
xa0;<&#
xa0;0.001), outperforming <i>Lacticaseibacillus rhamnosus</i> GG and <i>L. plantarum</i> type strain ATCC 14917<sup>T</sup>. We also confirmed the equivalence of laboratory-prepared and mass-produced TWK10 in ergogenic efficacy using <i>C. elegans</i> assay. In mice, oral administration of mass-produced TWK10 significantly enhanced exercise performance and glycogen storage in muscle and liver in a dose-dependent manner. In a clinical study involving healthy male adults, significant improvements in grip strength (1.1-fold, <i>p</i>&#
xa0;<&#
xa0;0.01) and exhaustion time (1.27-fold, <i>p</i>&#
xa0;<&#
xa0;0.01), and significant reductions in circulating lactate and ammonia levels were observed in the TWK10 group (1&#
xa0;&#
xd7;&#
xa0;10<sup>10</sup>&#
xa0;colony-forming unit/day) compared to the control group. Both humans and mice receiving mass-produced TWK10 showed improved body composition with increased muscle mass and reduced fat mass. In conclusion, TWK10 demonstrates superior longevous and ergogenic effects in <i>C. elegans</i> compared to reference strains. The consistent ergogenic efficacy of mass-produced TWK10 across <i>C. elegans</i>, mice, and humans, highlights the utility of <i>C. elegans</i> as a reliable model for probiotic research and industrial application.